Roivant Sciences (NASDAQ:ROIV) Major Shareholder Sells $7,800,077.25 in Stock

by · The Markets Daily

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) major shareholder Vivek Ramaswamy sold 353,745 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $22.05, for a total transaction of $7,800,077.25. Following the transaction, the insider owned 34,132,463 shares of the company’s stock, valued at $752,620,809.15. This represents a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

  • On Thursday, December 11th, Vivek Ramaswamy sold 774,142 shares of Roivant Sciences stock. The stock was sold at an average price of $21.64, for a total transaction of $16,752,432.88.
  • On Friday, December 12th, Vivek Ramaswamy sold 1,975,858 shares of Roivant Sciences stock. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68.
  • On Monday, November 17th, Vivek Ramaswamy sold 539,650 shares of Roivant Sciences stock. The shares were sold at an average price of $20.51, for a total transaction of $11,068,221.50.
  • On Friday, November 14th, Vivek Ramaswamy sold 1,027,670 shares of Roivant Sciences stock. The stock was sold at an average price of $20.33, for a total value of $20,892,531.10.
  • On Thursday, November 13th, Vivek Ramaswamy sold 287,283 shares of Roivant Sciences stock. The stock was sold at an average price of $20.81, for a total value of $5,978,359.23.

Roivant Sciences Stock Down 0.9%

Shares of NASDAQ ROIV traded down $0.20 during midday trading on Monday, hitting $21.90. The stock had a trading volume of 13,196,504 shares, compared to its average volume of 6,407,501. The company has a market capitalization of $15.23 billion, a PE ratio of -39.11 and a beta of 1.22. The stock has a 50 day simple moving average of $19.49 and a 200-day simple moving average of $14.81. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $22.56.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of research reports. JPMorgan Chase & Co. raised their price objective on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 18th. Bank of America raised their price target on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research note on Thursday, September 18th. The Goldman Sachs Group boosted their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday. Jefferies Financial Group increased their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Finally, Leerink Partners boosted their target price on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $24.81.

View Our Latest Stock Analysis on ROIV

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp grew its stake in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares during the period. Allworth Financial LP raised its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. lifted its holdings in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. CWM LLC grew its position in Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Roivant Sciences by 94.8% in the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after acquiring an additional 2,233 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

About Roivant Sciences

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Recommended Stories